On Monday, Eli Lilly and Co (NYSE:LLY) entered into a partnership agreement with Yabao Pharmaceuticals to develop mutually the most important glucokinase activator of Lilly’s (GKA), LY 2608204. According to the terms of partnership, Yabao will control the GKA market in China whereas Lilly will have the rights to develop GKA in all the other countries. As for now, both the companies will draft an initiation and a plan for development of the GKA market in China whereas Yabao will be responsible for acquiring all the funding. No disclosure has been made about the financial terms of the agreement by either of the companies.

In the last trading session, the stocks of Eli Lilly and Co (NYSE:LLY) were opened at a price of $62.61; the company was able to close the stocks at the same price. The company had a range of $47.53 to $63.38 for its 52 week period. Moreover, the total market capitalization of the company was recorded to be at 70.09 billion with a price earnings ratio of 17.51.

As for Genetic Technologies Limited (ADR)(NASDAQ:GENE), on Monday, during the first hour of trade, the share prices of Genetic Technologies Limited (ADR)(NASDAQ:GENE) jumped up by 19 percent and reached the price of $1.22. The highest price hit the numbers of $1.31 once the company announced its sales figures for the BREVAGen breast cancer test. As compared to the first quarter of the year, the sales figures for the second quarter increased by 37 percent. Consequently, the total sale for the fiscal year 2014 reached 3,935 tests.

On the last trade day, Genetic Technologies Limited (ADR)(NASDAQ:GENE)’s share started at $1.15 and closed at a reduced price of $1.14. As far as the beta and market capitalization of the company are concerned, the figures were reported to be 0.81 and 18.07 million. The company has a $0.97 to $3.00 range over a period of 52 weeks.

Coming to The Medicines Company (NASDAQ:MDCO), on Monday, the company announced that the European Commission, the Committee for Medicinal Products for Human Use and the European Medicines Agency have given Angiox the market authorization. According to the company, the renewal recommendation granted to Angiox by CHMP reaffirms that the risk-benefit analysis lies in the positive direction.

The committee gave its approval only after it had seen the review of safety, efficacy and clinical data. Moreover, the committee also had a look at the risk management graph of Angiox, prior to its authorization. Angiox is an anti-coagulation drug for adult patients. This drug was designed for patients undergoing the procedure of percutaneous coronary intervention. Moreover, this medicine is also used for patients suffering from ST-segment elevation myocardial infarction.

On the last trading day, the company opened its stocks at the price of $28.78 and closed at the price of $28.83. As far as the 52 week high and low of the company is concerned, the figures were reported to be at $41.28 and $23.53 respectively. The earnings per share of the company’s shares were $0.36 whereas its beta was 1.4.

Get Free Updates and Stock Alerts!

*We only send one email per week